The new Medicare GLP-1 Bridge Program went live on July 1, 2026, giving eligible Part D enrollees access to certain weight-loss medications for a flat $50 monthly copay.
Covered drugs include Wegovy (injections and tablets), Zepbound (KwikPen only), and all formulations of Foundayo. Beneficiaries must have a BMI of 35+ or a BMI over 30 with weight-related comorbidities, and their doctor must submit a prior authorization form to CMS.
The copay does not count toward the Part D deductible or out-of-pocket maximum, but it offers significant savings for those who qualify. The demonstration runs through December 31, 2027.
